Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

David Olmos, Sophie Postel-Vinay, L. Rhoda Molife, Scott H. Okuno, Scott M. Schuetze, M. Luisa Paccagnella, Gretchen N. Batzel, Donghua Yin, Kathryn Pritchard-Jones, Ian Judson, Francis P. Worden, Antonio Gualberto, Michelle Scurr, Johann S. de Bono, Paul Haluska

Research output: Contribution to journal › Article › peer-review

258 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study'. Together they form a unique fingerprint.

Medicine & Life Sciences